Source: Eur Respir J 2010; 35: 1206-1208
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Cottin V.. Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1206-1208

Member's Comments

No comment yet.

Related content which might interest you: A prognostic staging system for rheumatoid arthritis-associated interstitial lung disease Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management Year: 2018 Interstitial lung disease in patients with rheumatoid arthritis Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases Year: 2008 Mortality and clinical features in rheumatoid arthritis and interstitial lung disease Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Predicting outcomes in rheumatoid arthritis related interstitial lung disease Source: Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018 Year: 2019 Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease Source: Eur Respir J 2016; 47: 588-596 Year: 2016 Methotrexate and rheumatoid arthritis associated interstitial lung disease Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020 Year: 2021 Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease? Source: International Congress 2016 – Connective tissue disorders Year: 2016 Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new Source: Breathe, 16 (4) 200223; 10.1183/20734735.0223-2020 Year: 2020 Rituximab improves interstitial lung disease in rheumatoid arthritis patients Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management Year: 2018 Risk factors of interstitial lung diseases in patients with rheumatoid arthritis. Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004 Characteristics and predictors of outcome in rheumatoid arthritis related ILD Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Duration of rheumatoid arthritis and the risk of developing interstitial lung disease Source: ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020 Year: 2021 Rheumatoid arthritis-associated interstitial lung disease: time trends Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 Rheumatoid arthritis-associated lung disease Source: Eur Respir Rev 2015; 24: 1-16 Year: 2015 Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis Source: Eur Respir J 2002; 20: Suppl. 38, 587s Year: 2002 Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease Source: Eur Respir J 2010; 35: 1322-1328 Year: 2010 The value of biomarkers in the rheumatoid arthritis related interstitial pneumonia Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016